Qvt Financial LP Argenx Se Transaction History

Qvt Financial LP

$966 Million
Q2 2024

A detailed history of Qvt Financial LP transactions in Argenx Se stock. As of the latest transaction made, Qvt Financial LP holds 32,498 shares of ARGX stock, worth $18 Million. This represents 1.45% of its overall portfolio holdings.

Number of Shares

32,498

Previous 32,498 -0.0%

Holding current value

$18 Million

Previous $12.8 Million 9.22%

% of portfolio

1.45%

Previous 1.18%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$127.44 - $232.72 $1.69 Million - $3.09 Million	-13,283 Reduced 29.01%	32,498 $7.32 Million
Q4 2019 Feb 14, 2020	SELL	$106.59 - $164.21 $1.95 Million - $3.01 Million	-18,334 Reduced 28.6%	45,781 $7.35 Million
Q3 2019 Nov 14, 2019	SELL	$113.31 - $150.51 $2.36 Million - $3.13 Million	-20,811 Reduced 24.5%	64,115 $7.31 Million
Q1 2019 May 15, 2019	SELL	$98.85 - $134.59 $886,190 - $1.21 Million	-8,965 Reduced 9.55%	84,926 $10.6 Million
Q4 2018 Feb 14, 2019	SELL	$63.81 - $109.82 $3.57 Million - $6.15 Million	-55,980 Reduced 37.35%	93,891 $9.02 Million
Q3 2018 Nov 14, 2018	SELL	$75.5 - $96.63 $1.26 Million - $1.61 Million	-16,652 Reduced 10.0%	149,871 $11.4 Million
Q2 2018 Aug 14, 2018	BUY	$74.84 - $100.16 $5.5 Million - $7.36 Million	73,489 Added 78.99%	166,523 $13.8 Million
Q1 2018 May 15, 2018	SELL	$56.95 - $85.19 $4.93 Million - $7.37 Million	-86,526 Reduced 48.19%	93,034 $7.3 Million
Q4 2017 Feb 14, 2018	SELL	$22.57 - $63.56 $461,330 - $1.3 Million	-20,440 Reduced 10.22%	179,560 $11.3 Million
Q3 2017 Nov 14, 2017	BUY	$19.81 - $22.61 $3.96 Million - $4.52 Million	200,000	200,000 $3.93 Million

Others Institutions Holding ARGX

# of Institutions

381

Shares Held

31.6M

Call Options Held

303K

Put Options Held

429K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $30.6B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Qvt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Qvt Financial LP with notifications on news.

Account